This MedLibrary.org supplementary page on Talk:Kappa Opioid receptor is provided directly from the open source Wikipedia as a service to our readers. Please see the note below on authorship of this content, as well as the Wikipedia usage guidelines. To search for other content from our encyclopedia supplement, please use the form below:
Related Sponsors
Contents |
Capitalization
What's with the capitalization on the O? Miserlou 03:43, 6 November 2007 (UTC)
more to the point, whats with the k? what letter is that? its like a k but with the top chopped off. —Preceding unsigned comment added by 86.138.148.31 (talk) 12:23, 2 April 2008 (UTC)
... that would be a "kappa". 160.62.4.10 (talk) 11:56, 7 April 2008 (UTC)
Dysphoria
I'm not sure it's correct at all that kappa agonists don't induce dysphoria. I can find numerous papers by respected authors in the field within the last year that refer to kappa-induced dysphoria. Either the anonymous wikipedia editor is correct and the experts are under a misconception, or this page needs a serious rewrite. 160.62.4.10 (talk) 11:56, 7 April 2008 (UTC)
- Try to track down papers that describe how the dysphoria has been measured. If you find animal studies, take into account that dysphoria is a genuinely human term and that avoidance in animals can have other meanings. Сасусlе 12:45, 7 April 2008 (UTC)
- I have tracked down papers describing how dysphoria is measured. The Land et al. paper outlines a stress-induced mechanism of kappa-dependent dysphoria very well. Regardless of the rewarding aspects of Salvinorin A in humans, kappa opioid receptor agonists have been demonstrated to be dysphoric in mice! This must be changed!*
The differences between Sal A and other KOR agonists are clear. The rewarding vs. dysphoric effects are likely due to dose-response relationships that are complex. To outright state that KOR agonists are NOT dysphoric is simply not true. Several personal accounts from Sal A users describe intense dysphoric experiences, and rewarding experience when the Sal A has worn off.
This article needs to be rewritten.
Literally one out of every four sentences in this article talks about salvinorin A. This article is not entitled "salvinorin A", but "kappa opioid receptor". There's very little information about the kappa opioid receptor in the article, which was apparently written by someone who thinks the most noteworthy thing about this topic is whatever erowid says about it.
And the "Further Reading" section is longer than the actual article. --76.224.65.89 (talk) 01:52, 17 May 2008 (UTC)
Suggestion that naloxone...
I removed the uncited suggestion that Naloxone is effective at counteracting the effects of kappa agonists; on the Naloxone page it was suggest that the drug is effective at counteracting, specifically, salvia (ie: as a way to bring someone back from a hallucinogenic state), which seems a stretch, especially since the literature is mixed on whether or not it is effective in animal tests and other experiments, and ESPECIALLY when the drug itself is neither recommended, prescribed, or otherwise suggested to be used in such situations. SiberioS (talk) 04:10, 21 May 2008 (UTC)
Wikipedia content modification information:
- This page was last modified on 29 July 2008, at 16:36.
Wikipedia Authorship and Review
Wikipedia content provided here is not reviewed directly by MedLibrary.org. Wikipedia content is authored by an open community of volunteers and is not produced by or in any way affiliated with MedLibrary.org.
Wikipedia Usage Guidelines
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article on "Talk:Kappa Opioid receptor".
The URL for this specific entry is:
All Wikipedia text is available under the terms of the GNU Free Documentation License. (See Copyrights for details). Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc.
